|
🐜
|
Adam Meets Eph: An ADAM Substrate Recognition Module Acts as a Molecular Switch for Ephrin Cleavage In trans
10 auth.
P. W. Janes,
N. Saha,
W. Barton,
M. Kolev,
Sabine H. Wimmer-Kleikamp,
E. Nievergall,
...
C. Blobel,
J. Himanen,
M. Lackmann,
D. Nikolov
|
8 |
2005 |
8
🐜
|
|
🐜
|
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
27 auth.
Anna M. Paczulla,
Kathrin Rothfelder,
S. Raffel,
M. Konantz,
Julia Steinbacher,
Hui Wang,
Claudia Tandler,
M. Mbarga,
T. Schaefer,
M. Falcone,
E. Nievergall,
D. Dörfel,
Pauline Hanns,
J. Passweg,
C. Lutz,
...
J. Schwaller,
R. Zeiser,
B. Blazar,
M. Caligiuri,
S. Dirnhofer,
P. Lundberg,
L. Kanz,
L. Quintanilla‐Martinez,
A. Steinle,
A. Trumpp,
H. Salih,
C. Lengerke
|
8 |
2019 |
8
🐜
|
|
🐬
|
Concepts and consequences of Eph receptor clustering.
P. W. Janes,
E. Nievergall,
M. Lackmann
|
6 |
2012 |
6
🐬
|
|
🦁
|
Eph-dependent cell-cell adhesion and segregation in development and cancer
E. Nievergall,
M. Lackmann,
P. W. Janes
|
6 |
2011 |
6
🦁
|
|
🦁
|
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.
10 auth.
E. Nievergall,
H. Ramshaw,
A. Yong,
M. Biondo,
S. Busfield,
G. Vairo,
...
Angel F. Lopez,
T. Hughes,
D. White,
D. Hiwase
|
6 |
2014 |
6
🦁
|
|
🐜
|
Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors
13 auth.
P. W. Janes,
B. Griesshaber,
Lakmali Atapattu,
E. Nievergall,
L. Hii,
A. Mensinga,
Chanly Chheang,
B. Day,
A. Boyd,
P. Bastiaens,
...
C. Jørgensen,
T. Pawson,
M. Lackmann
|
6 |
2011 |
6
🐜
|
|
🦁
|
PTP1B regulates Eph receptor function and trafficking
9 auth.
E. Nievergall,
P. W. Janes,
Carolin Stegmayer,
M. E. Vail,
F. Haj,
S. Teng,
...
B. Neel,
P. Bastiaens,
M. Lackmann
|
6 |
2010 |
6
🦁
|
|
🐜
|
Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells.
9 auth.
Sabine H. Wimmer-Kleikamp,
E. Nievergall,
Kristina Gegenbauer,
S. Adikari,
Mariam Mansour,
T. Yeadon,
...
A. Boyd,
N. Patani,
M. Lackmann
|
5 |
2008 |
5
🐜
|
|
🐜
|
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
27 auth.
S. Heatley,
Teresa Sadras,
C. Kok,
E. Nievergall,
Kelly Quek,
P. Dang,
B. McClure,
N. Venn,
S. Moore,
J. Suttle,
T. Law,
A. Ng,
Walter Muskovic,
M. Norris,
T. Révész,
...
M. Osborn,
A. Moore,
R. Suppiah,
C. Fraser,
F. Alvaro,
T. Hughes,
C. Mullighan,
G. Marshall,
L. D. Pozza,
D. Yeung,
R. Sutton,
D. White
|
5 |
2017 |
5
🐜
|
|
🐜
|
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
34 auth.
H. Goldschmidt,
E. Mai,
U. Bertsch,
R. Fenk,
E. Nievergall,
D. Tichy,
B. Besemer,
J. Dürig,
R. Schroers,
I. von Metzler,
M. Hänel,
C. Mann,
A. Asemissen,
B. Heilmeier,
N. Weinhold,
...
S. Huhn,
K. Kriegsmann,
S. Luntz,
Tobias A W Holderried,
K. Trautmann-Grill,
D. Gezer,
M. Klaiber-Hakimi,
M. Müller,
Cyrus Khandanpour,
W. Knauf,
C. Scheid,
M. Munder,
T. Geer,
H. Riesenberg,
J. Thomalla,
M. Hoffmann,
M. Raab,
H. Salwender,
K. Weisel
|
5 |
2022 |
5
🐜
|
